Literature DB >> 19497244

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.

Jean-Pierre Lindenmayer1, Hong Liu-Seifert, Pandurang M Kulkarni, Bruce J Kinon, Virginia Stauffer, Sara E Edwards, Lei Chen, David H Adams, Haya Ascher-Svanum, Peter F Buckley, Leslie Citrome, Jan Volavka.   

Abstract

OBJECTIVE: To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence.
METHOD: A post hoc analysis of a randomized, double-blind, 8-week, fixed-dose study comparing olanzapine 10, 20, and 40 mg/day for patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) with suboptimal response to current treatment (N = 599) was conducted between September 12, 2003, and November 3, 2005, at 55 study centers in the United States. Nonadherence was defined as not taking medication as prescribed based on daily pill counts. Because there was no significant difference in nonadherence between dose groups, effects of nonadherence on efficacy and safety outcomes were examined using all 3 groups combined. Baseline demographics and symptom severity were investigated as potential risk factors for nonadherence.
RESULTS: During the 8-week study, 34.5% of patients were nonadherent at least once. Nonadherent patients had significantly less improvement compared to adherent patients as measured by change in Positive and Negative Syndrome Scale total score (-22.57 vs. -26.84, p = .002). Longer duration of nonadherence was associated with reduced likelihood of treatment response (odds ratio = 0.94, 95% CI = 0.90 to 0.99, p = .008). The early treatment discontinuation rate was higher in nonadherent compared to adherent patients (40.8% vs. 24.5%, p < .001). Adherent and nonadherent patients had comparable outcomes in most safety measures, except for weight change, for which adherent patients had greater weight gain than nonadherent patients (2.63 kg vs. 1.96 kg, p = .02). Greater depression severity at baseline (p = .01) and greater hostility level during the study were significant risk factors for nonadherence (p = .02).
CONCLUSIONS: Medication nonadherence had a significantly negative impact on treatment response, highlighting the importance of adherence to achieve satisfactory treatment outcome. Findings may also help clinicians identify patients at risk for nonadherence and utilize interventions to improve adherence. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00100776. ©Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497244     DOI: 10.4088/JCP.08m04221

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  59 in total

1.  Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population.

Authors:  Kei Yoshimatsu; Andrea Elser; Melanie Thomas; James Dilley; Deborah Barnes; Alexandra Ballinger; Steven Wozniak; Christina Mangurian
Journal:  Community Ment Health J       Date:  2019-05-17

2.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

Review 3.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

4.  Switching away from pipotiazine palmitate: a naturalistic study.

Authors:  Feras Ali Mustafa
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

5.  Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla).

Authors:  Ulrike Stentzel; Neeltje van den Berg; Lara N Schulze; Thea Schwaneberg; Franziska Radicke; Jens M Langosch; Harald J Freyberger; Wolfgang Hoffmann; Hans-Jörgen Grabe
Journal:  BMC Psychiatry       Date:  2018-05-29       Impact factor: 3.630

Review 6.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

7.  Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

Authors:  George Bartzokis; Po H Lu; Erika P Raven; Chetan P Amar; Nicole R Detore; Alexander J Couvrette; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2012-07-17       Impact factor: 4.939

8.  Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

Authors:  J Volavka; R A Van Dorn; L Citrome; R S Kahn; W W Fleischhacker; P Czobor
Journal:  Eur Psychiatry       Date:  2015-12-04       Impact factor: 5.361

9.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.